Investing.com -- CorMedix Inc (NASDAQ:CRMD) stock rose 5.7% on Monday after the biopharmaceutical company announced a $75 million share repurchase program.
The company’s board of directors has authorized the buyback of up to $75 million of its outstanding common stock through December 31, 2027. CorMedix expects to begin repurchasing shares as early as the first quarter of 2026.
"With a strong balance sheet, solid operating performance, and expected ongoing cash flow generation, we believe we are well positioned to execute this share repurchase program while continuing to advance our growth strategy," said Joseph Todisco, Chairman & CEO of CorMedix Therapeutics.
The company, which focuses on developing therapeutic products for life-threatening diseases and conditions, reported approximately $150 million in cash and cash equivalents as of December 31, 2025. CorMedix had 79.3 million common shares outstanding at that time.
The repurchase program allows for buybacks through privately negotiated transactions, block trades, open market purchases, or trading plans as permitted under securities laws. The company noted that the program does not require it to acquire any specific amount of shares and may be suspended or discontinued at any time.
Todisco added that the program provides a "disciplined way to return value to shareholders while preserving the financial flexibility to invest in our business, including potential inorganic opportunities."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

























